Onconova Therapeutics Inc ONTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ONTX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.90
- Day Range
- $0.92–0.98
- 52-Week Range
- $0.55–1.45
- Bid/Ask
- $0.80 / $0.97
- Market Cap
- $20.37 Mil
- Volume/Avg
- 163,004 / 82,914
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 89.99
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.onconova.com
Valuation
Metric
|
ONTX
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.40 |
Price/Sales | 89.99 |
Price/Cash Flow | — |
Price/Earnings
ONTX
Financial Strength
Metric
|
ONTX
|
---|---|
Quick Ratio | 2.61 |
Current Ratio | 2.79 |
Interest Coverage | — |
Quick Ratio
ONTX
Profitability
Metric
|
ONTX
|
---|---|
Return on Assets (Normalized) | −53.74% |
Return on Equity (Normalized) | −80.04% |
Return on Invested Capital (Normalized) | −80.04% |
Return on Assets
ONTX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hkjkxtffk | Gbcg | $571.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hphghwpq | Tblckl | $107.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jpfkkqrtf | Mpqtvk | $106.1 Bil | |
MRNA
| Moderna Inc | Ynxtnrpll | Cwwp | $42.3 Bil | |
ARGX
| argenx SE ADR | Lhthnvqx | Zbvf | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Pprgpvdx | Zfvs | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qlpvzhtb | Cqgplhp | $19.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fsmwbtts | Pdwkh | $16.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bbvqlvgfm | Cbjtmr | $13.6 Bil | |
INCY
| Incyte Corp | Lbjcxpfmw | Wrbcgl | $12.8 Bil |